文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

自拟清源生华汤对脓毒症凝血功能障碍患者的影响

[Effect of self-made Qingyuan Shenghua decoction on coagulation dysfunction in patients with sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论在脓毒症凝血功能障碍患者中,加用自拟清源生华汤7天可改善凝血与炎症指标、降低APACHEⅡ和SOFA评分、缩短ICU住院时间,但MODS发生率和28天死亡率无统计学差异。

两组均接受脓毒症基础治疗,观察组加用自拟清源生华汤(每日一剂,早晚各100 mL),对照组给予等量生理盐水,疗程7天。结果显示观察组治疗后PT、APTT、INR、D-二聚体、WBC、CRP、PCT均低于对照组,Fib、PLT高于对照组,APACHEⅡ和SOFA评分改善更明显,ICU住院时间缩短(12.22±9.48天 vs 20.22±15.35天,P<0.05)。但MODS发生率和28天死亡率两组无统计学差异(均P>0.05)。

要点

  • 观察组治疗后PT 16.01±1.08 s、APTT 55.33±15.29 s、INR 1.30±0.21,均低于对照组的19.21±1.38 s、79.41±12.69 s、1.65±0.22(均P<0.05)。
  • 观察组治疗后Fib 2.87±0.89 g/L高于对照组5.44±1.13 g/L,D-二聚体2.56±1.67 mg/L低于对照组6.41±2.42 mg/L(均P<0.05)。
  • 观察组治疗后APACHEⅡ评分10.29±1.86、SOFA评分5.51±1.08,均低于对照组的15.35±2.06和7.65±1.58(均P<0.05)。
  • 观察组ICU住院时间12.22±9.48天,短于对照组20.22±15.35天(P<0.05)。
  • MODS发生率35.0%(14/40)vs 47.5%(19/40)、28天死亡率45.0%(18/40)vs 47.5%(19/40),两组无统计学差异(均P>0.05)。

适用人群与场景

  • 原文未提及明确的纳入标准、排除标准及病情阶段分层。

诊断标准与关键阈值

  • 原文未提及脓毒症诊断标准的具体名称及凝血功能障碍的界定阈值。

处置流程与药物剂量

  • 第一步:两组均接受脓毒症基础治疗。
  • 第二步:观察组在基础治疗上加用自拟清源生华汤,每日一剂,100 mL晨服、100 mL晚服;对照组给予等量生理盐水。
  • 第三步:两组均治疗7天。
  • 第四步:治疗前后检测PT、APTT、INR、Fib、D-二聚体、PLT、WBC、CRP、PCT,计算APACHEⅡ和SOFA评分,记录ICU住院时间、MODS发生率和28天死亡率。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 干预与对照:两组均接受脓毒症基础治疗,观察组加用自拟清源生华汤每日一剂早晚各100 mL,对照组给予等量生理盐水,疗程7天。
  • 主要凝血指标结果:治疗后观察组PT 16.01±1.08 s vs 对照组19.21±1.38 s,APTT 55.33±15.29 s vs 79.41±12.69 s,INR 1.30±0.21 vs 1.65±0.22,Fib 2.87±0.89 g/L vs 5.44±1.13 g/L,D-二聚体2.56±1.67 mg/L vs 6.41±2.42 mg/L,PLT 125.79±18.51×10⁹/L vs 95.46±18
  • 炎症指标结果:治疗后观察组WBC 7.50±0.78×10⁹/L vs 对照组12.75±4.09×10⁹/L,CRP 21.27±9.32 mg/L vs 65.44±13.40 mg/L,PCT 1.15±0.58 μg/L vs 6.31±1.29 μg/L,均P<0.05。
  • 评分与住院时间:治疗后观察组APACHEⅡ评分10.29±1.86 vs 对照组15.35±2.06,SOFA评分5.51±1.08 vs 7.65±1.58,ICU住院时间12.22±9.48天 vs 20.22±15.35天,均P<0.05。
  • MODS发生率35.0%(14/40)vs 47.5%(19/40),28天死亡率45.0%(18/40)vs 47.5%(19/40),两组差异无统计学意义(均P>0.05)。

证据类型、等级与局限

  • 证据类型:单中心随机对照试验。

对床旁实践的改变

  • 在脓毒症合并凝血功能障碍患者接受基础治疗的前提下,可考虑加用自拟清源生华汤每日一剂(早晚各100 mL)治疗7天,以期改善凝血和炎症指标、降低APACHEⅡ和SOFA评分、缩短ICU住院时间。
  • 原文未证实该方能降低MODS发生率或28天死亡率(两组差异无统计学意义),不应据此改变对MODS和死亡的预期管理。
  • 自拟清源生华汤的组方、制备方法及不良反应原文未提及,使用时需注意制剂来源与安全性监测。
  • 适用与不适用人群:原文仅纳入脓毒症合并凝血功能障碍的ICU患者,未提及排除人群,不能外推至其他人群。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To observe the effects of self-made Qingyuan Shenghua decoction on coagulation dysfunction in patients with sepsis, and to explore its possible mechanism.

METHODS: Eighty patients with sepsis and coagulation dysfunction admitted to the department of critical care medicine of Chengdu First People's Hospital from March 2018 to April 2020 were enrolled. The patients were divided into control group and observation group according to random number table method, with 40 cases in each group. Patients in both groups received basic treatment for sepsis. On this basis, the observation group was administrated with self-made Qingyuan Shenghua decoction, one dose a day, 100 mL in the morning and 100 mL in the evening; the control group was given the same amount of normal saline. Both groups were treated for 7 days. Prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (Fib), D-dimer, platelet count (PLT), white blood cell count (WBC), C-reactive protein (CRP), and procalcitonin (PCT) were measured before and after treatment, and acute physiology and chronic health evaluation II (APACHE II) and sequential organ failure assessment (SOFA) were calculated. The length of intensive care unit (ICU) stay, the incidence of multiple organ dysfunction syndrome (MODS) and 28-day mortality was recorded.

RESULTS: The indexes of coagulation function and inflammation in the two groups were significantly improved after treatment, the improvement of various indexes in the observation group were better than those in the control group [PT (s): 16.01±1.08 vs. 19.21±1.38, APTT (s): 55.33±15.29 vs. 79.41±12.69, INR: 1.30±0.21 vs. 1.65±0.22, Fib (g/L): 2.87±0.89 vs. 5.44±1.13, D-dimer (mg/L): 2.56±1.67 vs. 6.41±2.42, PLT (×109/L): 125.79±18.51 vs. 95.46±18.50, WBC (×109/L): 7.50±0.78 vs. 12.75±4.09, CRP (mg/L): 21.27±9.32 vs. 65.44±13.40, PCT (μg/L): 1.15±0.58 vs. 6.31±1.29], and the differences were statistically significant (all P < 0.05). After treatment, APACHE II and SOFA scores in the two groups decreased significantly compared with those before treatment, and the decrease in the observation group were more obvious than those in the control group (APACHE II score: 10.29±1.86 vs. 15.35±2.06, SOFA score: 5.51±1.08 vs. 7.65±1.58, both P < 0.05). The length of ICU stay was shortened in the observation group than that in the control group (days: 12.22±9.48 vs. 20.22±15.35, P < 0.05). The incidence of MODS [35.0% (14/40) vs. 47.5% (19/40)] and the 28-day mortality [45.0% (18/40) vs. 47.5% (19/40)] was lower than that of the control group, but there was no statistical difference (both P > 0.05).

CONCLUSIONS: Self-made Qingyuan Shenghua decoction can effectively improve the prognosis of patients with coagulation dysfunction and sepsis, and its mechanism may be related to inhibition of inflammatory reaction and improvement of coagulation function.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhou Z, Lu P, Yao J, et al. [Effect of self-made Qingyuan Shenghua decoction on coagulation dysfunction in patients with sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34590561. doi:10.3760/cma.j.cn121430-20201231-00790

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。